세계의 위내 체류형 약물전달 시스템 아웃소싱 시장 규모는 2024년에 13억 7,000만 달러로, 예측 기간 중 CAGR은 5.51%로 2030년에는 18억 9,000만 달러에 달할 것으로 예측됩니다. 세계 위내 체류형 약물전달 시스템 아웃소싱 시장은 제약 및 헬스케어 산업에서 역동적이고 빠르게 발전하고 있는 분야입니다. 위내 체류형 약물전달 시스템은 약물을 장기간 위장에 머무르게 하여 방출 제어 및 표적 치료 효과를 촉진하는 특수 제형 및 기술을 말합니다. 이 시장 부문은 약물의 생체 이용률을 높이고, 환자의 순응도를 개선하며, 부작용을 감소시키는 새로운 약물전달 시스템에 대한 수요가 증가함에 따라 괄목할 만한 성장세를 보이고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 13억 7,000만 달러 |
| 시장 규모 : 2030년 | 18억 9,000만 달러 |
| CAGR: 2025-2030년 | 5.51% |
| 급성장 부문 | 정제 |
| 최대 시장 | 북미 |
소화기 질환과 같은 만성질환 증가로 인해 효과적이고 환자 친화적인 약물전달 솔루션이 요구되고 있습니다. 또한 인구 고령화와 첨단 제약 기술에 대한 인식이 높아지면서 위내 체류형 약물전달 시스템에 대한 수요가 증가하고 있습니다. 제약업계에서는 전문 지식을 활용하고 시장 출시 시간을 단축하기 위해 전문 위탁연구기관(CRO)이나 수탁제조기관(CMO)에 이러한 시스템의 개발 및 제조를 위탁하는 사례가 증가하고 있습니다.
CRO와 CMO는 R&D, 기술 선택, 규제 준수, 품질 보증을 포괄하는 엔드투엔드 솔루션을 제공하는 데 있으며, 매우 중요한 역할을 하고 있습니다.에서 매우 중요한 역할을 담당하고 있습니다. 이를 통해 제약회사는 신약개발과 임상개발이라는 핵심 역량에 집중할 수 있으며, 위내 체류형 약물전달에 대한 전문지식은 아웃소싱 파트너에게 의존할 수 있습니다.
또한 지역 확장, 전략적 제휴, 연구개발 활동에 대한 투자가 시장의 급격한 성장에 기여하고 있습니다. 부유 시스템, 생체 접착 시스템, 확장형 시스템 등 새로운 위내 체류형 약물전달 기술의 개발로 인해 시장은 기술 혁신의 급격한 증가를 목격하고 있습니다.
소화기 질환 유병률 증가
지적재산권 관련 우려
표적 약물전달에 대한 수요 증가
Global Gastroretentive Drug Delivery Systems Outsourcing Market was valued at USD 1.37 billion in 2024 and is expected to reach USD 1.89 billion by 2030 with a CAGR of 5.51% during the forecast period. The Global Gastroretentive Drug Delivery Systems Outsourcing Market is a dynamic and rapidly evolving sector within the pharmaceutical and healthcare industry. Gastroretentive drug delivery systems refer to specialized formulations and technologies that enable drugs to be retained in the stomach for an extended period, facilitating controlled release and targeted therapeutic effects. This market segment is witnessing significant growth due to the increasing demand for novel drug delivery systems that enhance drug bioavailability, improve patient compliance, and reduce side effects.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 1.37 Billion |
| Market Size 2030 | USD 1.89 Billion |
| CAGR 2025-2030 | 5.51% |
| Fastest Growing Segment | Tablets |
| Largest Market | North America |
the rising prevalence of chronic diseases, such as gastrointestinal disorders, which require effective and patient-friendly drug delivery solutions. Moreover, an aging population and increasing awareness of advanced pharmaceutical technologies are propelling the demand for gastroretentive drug delivery systems. The pharmaceutical industry is increasingly outsourcing the development and manufacturing of these systems to specialized contract research organizations (CROs) and contract manufacturing organizations (CMOs) to leverage their expertise and reduce time-to-market.
The market is characterized by a diverse range of outsourcing services, including formulation development, preclinical and clinical testing, and commercial-scale production of gastroretentive drug delivery systems. CROs and CMOs are playing a pivotal role in offering end-to-end solutions that encompass research and development, technology selection, regulatory compliance, and quality assurance. As a result, pharmaceutical companies can focus on their core competencies in drug discovery and clinical development, while relying on outsourcing partners for specialized expertise in gastroretentive drug delivery.
Furthermore, regional expansion, strategic collaborations, and investments in research and development activities are contributing to the market's rapid growth. The market is witnessing a surge in innovation, with the development of novel gastroretentive drug delivery technologies, including floating systems, bio adhesive systems, and expandable systems.
Key Market Drivers
Rising Prevalence of Gastrointestinal Disorders
The rising prevalence of gastrointestinal disorders is a pivotal driver behind the growth of the Global Gastroretentive Drug Delivery Systems Outsourcing Market. Gastrointestinal conditions, such as gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease, and peptic ulcers, are becoming increasingly common worldwide. These disorders can significantly impact an individual's quality of life and managing them effectively often requires specialized pharmaceutical interventions.
According to World Gastroenterology Organisation, overall, 49% of females and 36.6% of males met criteria for at least one FGID - the most common disorders in all regions being functional constipation, functional dyspepsia, proctalgia fugax, functional diarrhea and IBS at prevalence rates of 11.7%, 7.2%, 5.9%, 4.7% and 4.1, respectively.
Gastroretentive drug delivery systems play a crucial role in addressing the challenges associated with treating gastrointestinal disorders. These innovative systems allow drugs to remain in the stomach for an extended period, ensuring localized treatment and controlled release of therapeutic agents. This approach not only enhances the bioavailability of drugs but also minimizes side effects and maximizes the effectiveness of treatment, providing much-needed relief to patients suffering from gastrointestinal ailments.
Key Market Challenges
Intellectual Property Concerns
In the competitive world of pharmaceuticals, companies invest heavily in research and development to create proprietary innovations, including gastroretentive drug delivery technologies. These innovations often form the core of their product portfolio and protecting them through IP rights is essential for maintaining a competitive edge. The fear of losing exclusive rights to these innovations can lead to hesitancy in sharing proprietary information with outsourcing partners, potentially hampering collaboration.
Collaborations between pharmaceutical companies and contract research organizations (CROs) or contract manufacturing organizations (CMOs) require a degree of information exchange. For the successful development and manufacturing of gastroretentive drug delivery systems, there's a need to share critical data, formulation knowledge, and technical expertise. However, striking the right balance between knowledge sharing and IP protection can be challenging. Pharmaceutical companies must carefully manage their IP while ensuring that their outsourcing partners have the necessary information to deliver high-quality products.
Key Market Trends
Increasing Demand for Targeted Drug Delivery
The Global Gastroretentive Drug Delivery Systems Outsourcing Market is experiencing a significant boost due to the increasing demand for targeted drug delivery solutions. This surge in demand is fueled by several factors and represents a key driving force shaping the future of the pharmaceutical outsourcing industry.
One of the most prominent factors driving the increasing demand for targeted drug delivery is the growing recognition of the limitations of traditional drug delivery methods. Conventional oral drug delivery often lacks specificity, with drugs being absorbed throughout the gastrointestinal tract. This can lead to reduced drug bioavailability and increased side effects, making it less than ideal for many therapeutic applications.
gastroretentive drug delivery systems offer a highly effective means of targeting specific regions within the gastrointestinal tract, particularly the stomach. These systems allow drugs to remain in the stomach for an extended duration, ensuring that they are delivered precisely where they are needed. This localized, site-specific approach not only enhances drug bioavailability but also minimizes unwanted side effects, improving the overall therapeutic outcomes for patients.
In this report, the Global Gastroretentive Drug Delivery Systems Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Gastroretentive Drug Delivery Systems Outsourcing Market.
Global Gastroretentive Drug Delivery Systems Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: